1. "Solid Tumor Oncology Division"
Formats
  1. Journal Article (10831)
  2. Meeting Abstract (9435)
  3. Review (542)
  4. Book Section (410)
  5. Editorial (324)
  6. Guidelines (154)
  7. Correspondence (115)
  8. Conference Paper (106)
  9. Research Letter (60)
  10. Miscellaneous (53)
  11. Book Whole (27)
Groups
  1. Solid Tumor Oncology Division (22057)
  2. Department of Medicine (22035)
  3. GSK Faculty (5880)
  4. Genitourinary Oncology Service (5608)
  5. Survivorship Research (5184)
  6. Gastrointestinal Oncology Service (4640)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. Clifford Hudis (905)
  4. Jedd Wolchok (905)
  5. Mark Kris (869)
  6. Leonard Saltz (790)

More People

Years
  1. 2025 (445)
  2. 2024 (1382)
  3. 2023 (1380)
  4. 2022 (1573)
  5. 2021 (1517)
  6. 2020 (1535)

More Years

Publications
  1. Journal of Clinical Oncology (5227)
  2. Annals of Oncology (1294)
  3. Cancer Research (1012)
  4. Clinical Cancer Research (768)
  5. Journal of Thoracic Oncology (530)
  6. Gynecologic Oncology (441)

More Publications

Publishers
  1. American Society of Clinical Oncology (5507)
  2. Elsevier Inc. (2651)
  3. American Association for Cancer Research (2316)
  4. Oxford University Press (1810)
  5. Nature Publishing Group (1026)
  6. Springer (975)

More Publishers

Results (22057)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Survival following stage II/III colon cancer (CC): Accent-based comparison versus matched general population (MGP)
    Meeting Abstract

    Renfro, L. A.; Grothey, A.; Kerr, D. J.; Haller, D. G.; Andre, T.; Van Cutsem, E.; Saltz, L.; Labianca, R.; Loprinzl, C. L.; Alberts, S. R.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • MGMT immunohistochemistry (IHC) and exclusion of pancreatic NET (PanNET) patients from treatment with temozolomide-based therapy
    Meeting Abstract

    Reidy, D. L.; Basturk, O.; Kriplani, A.; Abou-Alfa, G. K.; Jarnagin, W. R.; Allen, P. J.; Saltz, L.; Klimstra, D. S.; Zhang, L. Y.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • ARN-509 in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) with and without prior abiraterone acetate (AA) treatment
    Meeting Abstract

    Rathkopf, D. E.; Antonarakis, E. S.; Shore, N. D.; Tutrone, R. F.; Alumkal, J. J.; Ryan, C. J.; Saleh, M. N.; Hauke, R. J.; Bandekar, R.; Maneval, E. C.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Targeting reciprocal feedback inhibition in the clinic: ARN509 and PI3K pathway inhibition in patients with metastatic castration-resistant prostate cancer (mCRPC)
    Meeting Abstract

    Rathkopf, D. E.; Carver, B. S.; Chen, Y.; Morris, M. J.; Danila, D. C.; Slovin, S. F.; Autio, K. A.; DeNunzio, M.; Sawyers, C. L.; Scher, H. I.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase 1 study of the BRAF inhibitor dabrafenib (D) with or without the MEK inhibitor trametinib (T) in combination with ipilimumab (Ipi) for V600E/K mutation positive unresectable or metastatic melanoma (MM)
    Meeting Abstract

    Puzanov, I.; Callahan, M. K.; Linette, G. P.; Patel, S. P.; Luke, J. J.; Sosman, J. A.; Wolchok, J. D.; Hamid, O.; Minor, D. R.; Orford, K. W.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • A randomized phase II study of GDC-0980 versus everolimus in metastatic renal cell carcinoma (mRCC) patients (pts) after VEGF-targeted therapy (VEGF-TT)
    Meeting Abstract

    Powles, T.; Oudard, S.; Escudier, B. J.; Brown, J. E.; Hawkins, R. E.; Castellano, D. E.; Ravaud, A.; Staehler, M. D.; Rini, B. I.; Lin, W.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Assessment of overall survival from time of metastastasis in mucosal, uveal, and cutaneous melanoma
    Meeting Abstract

    Postow, M. A.; Kuk, D.; Bogatch, K.; Carvajal, R. D.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • HER2 mutations in lung adenocarcinoma: A report from the Lung Cancer Mutation Consortium (LCMC)
    Meeting Abstract

    Pillai, R. N.; Behera, M.; Berry, L. D.; Rossi, M. R.; Kris, M. G.; Bunn, P. A.; Khuri, F. R.; Ramalingam, S. S.
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • Phase I trial of the hedgehog (Hh) inhibitor, LDE225, in combination with etoposide and cisplatin (EP) for initial treatment of extensive stage small cell lung cancer (ES-SCLC)
    Meeting Abstract

    Pietanza, M. C.; Krug, L. M.; Varghese, A. M.; Fleisher, M.; Teitcher, J. B.; Holodny, A.; Sima, C. S.; Litvak, A. M.; Ng, K. K.; Patel, P. R.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save
  • SELECT: A multicenter phase II trial of adjuvant erlotinib in resected early-stage EGFR mutation-positive NSCLC
    Meeting Abstract

    Pennell, N. A.; Neal, J. W.; Chaft, J. E.; Azzoli, C. G.; Jänne, P. A.; Govindan, R.; Evans, T. L.; Costa, D. B.; Rosovsky, R. P. G.; Wakelee, H. A.; more...
    Journal of Clinical Oncology (2014)

    Fulltext@MSK | Save